In short
This article summarizes several clinical trials investigating vepdegestrant (ARV-471), an oral medication being studied for the treatment of advanced or metastatic estrogen receptor-positive (ER+), HER2-negative breast cancer. Vepdegestrant is a new type of drug called a proteolysis targeting chimera (PROTAC) that works by degrading the estrogen receptor. The trials are evaluating vepdegestrant alone and in combination with other cancer drugs to determine its safety, effectiveness, and optimal dosing in patients whose cancer has progressed after prior treatments.
Introduction
Vepdegestrant, also known as ARV-471 or PF-07850327, is an innovative drug being developed for the treatment of advanced breast cancer. It belongs to a new class of medications called oral proteolysis targeting chimeras (PROTACs). This article will provide an overview of vepdegestrant, its potential benefits, and ongoing clinical trials for patients with breast cancer.
Mechanism of Action
Vepdegestrant works by targeting and degrading the estrogen receptor (ER) in breast cancer cells. The estrogen receptor plays a crucial role in the growth and survival of many breast cancers. By breaking down this receptor, vepdegestrant may help slow or stop the growth of ER-positive breast tumors.
Indications
Vepdegestrant is being studied for the treatment of estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer. This type of breast cancer is hormone-sensitive and accounts for a significant proportion of breast cancer cases.
Clinical Trials
Several clinical trials are currently evaluating the safety and efficacy of vepdegestrant:
- VERITAC-2: A Phase 3 study comparing vepdegestrant to fulvestrant in patients who have progressed after prior endocrine-based treatment.
- VERITAC-3: A Phase 3 study comparing vepdegestrant plus palbociclib to letrozole plus palbociclib in patients who have not received prior systemic treatment for advanced disease.
- TACTIVE-U: An umbrella study investigating vepdegestrant in combination with other anticancer treatments, including abemaciclib, ribociclib, samuraciclib, and PF-07220060.
- A Phase 1b trial studying vepdegestrant in combination with everolimus.
Efficacy
The ongoing clinical trials aim to assess the efficacy of vepdegestrant through various endpoints, including:
- Progression-free survival (PFS): The time from the start of treatment until the cancer progresses or the patient dies.
- Overall survival (OS): The length of time patients live after starting treatment.
- Objective response rate (ORR): The proportion of patients whose tumors shrink or disappear with treatment.
- Clinical benefit rate (CBR): The percentage of patients who achieve a complete response, partial response, or stable disease for at least 24 weeks.
- Duration of response (DOR): How long the tumor response lasts.
Results from these trials will help determine how effective vepdegestrant is compared to existing treatments and in combination with other therapies.
Safety and Side Effects
The safety profile of vepdegestrant is still being evaluated in clinical trials. Researchers are monitoring for adverse events, laboratory abnormalities, and ECG changes. Common side effects of breast cancer treatments may include fatigue, nausea, and changes in blood cell counts. However, the specific side effects of vepdegestrant will become clearer as more data from clinical trials become available.
Combination Therapies
Vepdegestrant is being studied in combination with several other cancer drugs to potentially enhance its effectiveness:
- CDK4/6 inhibitors: Such as palbociclib, abemaciclib, and ribociclib.
- mTOR inhibitors: Like everolimus.
- Other investigational drugs: Including samuraciclib and PF-07220060.
These combinations aim to target multiple pathways involved in cancer growth and potentially overcome resistance to single-agent treatments.
Conclusion
Vepdegestrant (ARV-471) represents a promising new approach to treating ER-positive, HER2-negative advanced breast cancer. As a PROTAC molecule, it offers a novel mechanism for targeting the estrogen receptor. Ongoing clinical trials will provide crucial information about its efficacy, safety, and potential role in breast cancer treatment, both as a single agent and in combination with other therapies. Patients interested in learning more about vepdegestrant should discuss potential clinical trial opportunities with their oncologist.